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Abstract
Background: Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote
immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further
development as an oncolytic immunotherapy in this study as it is highly lytic, infects human tumor cells broadly,
kills mainly by necrosis and is a potent activator of both innate and adaptive immunity. HSV-1 also has a large
capacity for the insertion of additional, potentially therapeutic, exogenous genes. Finally, HSV-1 has a proven safety
and efficacy profile in patients with cancer, talimogene laherparepvec (T-VEC), an oncolytic HSV-1 which expresses
GM-CSF, being the only oncolytic immunotherapy approach that has received FDA approval. As the clinical efficacy
of oncolytic immunotherapy has been shown to be further enhanced by combination with immune checkpoint
inhibitors, developing improved oncolytic platforms which can synergize with other existing immunotherapies is a
high priority. In this study we sought to further optimize HSV-1 based oncolytic immunotherapy through multiple
approaches to maximize: (i) the extent of tumor cell killing, augmenting the release of tumor antigens and danger
-associated molecular pattern (DAMP) factors; (ii) the immunogenicity of tumor cell death; and (iii) the resulting
systemic anti-tumor immune response.
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Methods: To sample the wide diversity amongst clinical strains of HSV-1, twenty nine new clinical strains isolated
from cold sores from otherwise healthy volunteers were screened across a panel of human tumor cell lines to
identify the strain with the most potent tumor cell killing ability, which was then used for further development.
Following deletion of the genes encoding ICP34.5 and ICP47 to provide tumor selectivity, the extent of cell killing
and the immunogenicity of cell death was enhanced through insertion of a gene encoding a truncated, constitutively
highly fusogenic form of the envelope glycoprotein of gibbon ape leukemia virus (GALV-GP-R−). A number of further
armed derivatives of this virus were then constructed intended to further enhance the anti-tumor immune response
which was generated following fusion-enhanced, oncolytic virus replication-mediated cell death. These viruses
expressed GMCSF, an anti-CTLA-4 antibody-like molecule, CD40L, OX40L and/or 4-1BB, each of which is expected to
act predominantly at the site and time of immune response initiation. Expression of these proteins was confirmed by
ELISA and/or western blotting. Immunogenic cell death was assessed by measuring the levels of HMGB1 and ATP from
cell free supernatants from treated cells, and by measuring the surface expression of calreticulin. GALV-GP-R− mediated
cell to cell fusion and killing was tested in a range of tumor cell lines in vitro. Finally, the in vivo therapeutic
potential of these viruses was tested using human A549 (lung cancer) and MDA-MB-231(breast cancer) tumor
nude mouse xenograft models and systemic anti-tumor effects tested using dual flank syngeneic 4434
(melanoma), A20 (lymphoma) mouse tumor models alone and in combination with a murine anti-PD1
antibody, and 9 L (gliosarcoma) tumors in rats.
Results: The twenty nine clinical strains of HSV-1 isolated and tested demonstrated a broad range of tumor
cell killing abilities allowing the most potent strain to be identified which was then used for further development.
Oncolytic ability was demonstrated to be further augmented by the expression of GALV-GP-R− in a range of tumor cell
lines in vitro and in mouse xenograft models in nude mice. The expression of GALV-GP-R− was also demonstrated to
lead to enhanced immunogenic cell death in vitro as confirmed by the increased release of HMGB1 and ATP and
increased levels of calreticulin on the cell surface. Experiments using the rat 9 L syngeneic tumor model demonstrated
that GALV-GP-R− expression increased abscopal uninjected (anenestic) tumor responses and data using mouse 4434
tumors demonstrated that virus treatment increased CD8+ T cell levels both in the injected and uninjected tumor, and
also led to increased expression of PD-L1. A combination study using varying doses of a virus expressing GALV-GP-R− and
mGM-CSF and an anti-murine PD1 antibody showed enhanced anti-tumor effects with the combination which was most
evident at low virus doses, and also lead to immunological memory. Finally, treatment of mice with derivatives of this
virus which additionally expressed anti-mCTLA-4, mCD40L, m4-1BBL, or mOX40L demonstrated enhanced activity,
particularly in uninjected tumors.
Conclusion: The new HSV-1 based platform described provides a potent and versatile approach to developing new
oncolytic immunotherapies for clinical use. Each of the modifications employed was demonstrated to aid in optimizing
the potential of the virus to both directly kill tumors and to lead to systemic therapeutic benefit. For clinical use, these
viruses are expected to be most effective in combination with other anti-cancer agents, in particular PD1/L1-targeted
immune checkpoint blockade. The first virus from this program (expressing GALV-GP-R− and hGM-CSF) has entered
clinical development alone and in combination with anti-PD1 therapy in a number of tumor types (NCT03767348).
Keywords: Oncolytic viruses, Herpes simplex-1, Immunotherapy, Anenestic effect
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Introduction
Oncolytic immunotherapy has shown single agent
clinical activity and synergy with immune checkpoint
blockade. However, not all patients respond, and most of
the clinical experience has been in melanoma. With the
objective of maximally activating a patient’s immune sys-
tem against their own cancer to enhance synergy with
anti-PD1/L1 blockade, we have developed a new oncoly-
tic immunotherapy platform based on herpes simplex
virus type 1 (HSV-1). This has the dual objectives of ro-
bustly killing tumor to provide abundant release of
tumor antigens, and potently activating the immune sys-
tem against these tumor antigens once released. To aug-
ment the natural ability of HSV-1 to kill tumors and
activate anti-tumor immunity, the viruses developed are
armed with therapeutic genes with the expectation that
‘arming’ will be essential to maximizing clinical activity.
Initially, we sampled the genetic variation between
strains of HSV-1 by screening twenty nine new clinical
strains isolated from volunteers who suffer from cold
sores across a panel of human tumor cell lines to iden-
tify the strain to be developed. This strain (RH018A)
was then engineered for oncolytic use by deletion of the
genes encoding ICP34.5 to reduce pathogenicity, delet-
ing the ICP47 encoding gene to enhance viral and tumor
antigen presentation by major histocompatibility com-
plex-I (MHC-I), and inserting a gene encoding a potent
fusogenic glycoprotein derived from gibbon ape
leukemia virus (GALV-GP-R−). Expression of GALV-GP-
R− caused increased immunogenic cell death, assessed
by the release of danger-associated molecular pattern fac-
tors, activated anti-tumor immunity, and enhanced sys-
temic therapeutic activity against rat and murine tumors
in vivo. Additionally, the virus induced expression of PD-
L1, and demonstrated enhanced activity in combination
with PD-1 blockade. A virus expressing GALV-GP-R− and
hGM-CSF is currently in a Phase 1/2 clinical trial
(NCT03767348). Further viruses were constructed based
on this virus which additionally express an anti-CTLA-4
antibody or immune co-stimulatory pathway activating li-
gands, each of which is expected to act at the site and time
of immune response initiation in the injected tumor and
draining lymph nodes. These viruses demonstrated further
increased activity in mice, particularly an enhanced ane-
nestic effect. This data supports the potential for im-
proved therapeutic activity of this new oncolytic
immunotherapy platform and demonstrate its use to ex-
press immune modulatory proteins which may provide a
generalized strategy to improve therapy for patients with
cancer. There have been significant advances in the im-
munotherapy of cancer, most notably through the clinical
development of immune checkpoint inhibitors targeting
cytotoxic T lymphocyte antigen 4 (CTLA-4) and the pro-
grammed cell death 1 (PD-1)/PD-1 ligand (PD-L1)
pathway [1, 2]. While durable clinical responses have been
observed across numerous solid and hematologic malig-
nancies, many tumors do not respond or develop resist-
ance over time [3]. The absence of tumor-specific T cells
within the tumor microenvironment appears to be an im-
portant feature associated with innate and acquired resist-
ance to checkpoint blockade. New strategies that can
induce anti-tumor immune responses with which anti-
PD-1/L1 therapy can synergize, reverse the immune-defi-
cient tumor microenvironment, and which can re-estab-
lish tumor sensitivity to systemic anti-PD-1/L1 therapy
are therefore needed. One promising approach is virus-
based oncolytic immunotherapy [4]. Oncolytic viruses
preferentially replicate in tumors as compared to normal
tissue, and promote immunogenic cell death and induc-
tion of host systemic anti-tumor immunity. The oncolytic
immunotherapy approach has been clinically validated as
demonstrated by the U.S. Food and Drug Administration
(FDA) and European Medicines Agency (EMA) approval
of talimogene laherparepvec (T-VEC), an oncolytic herpes
simplex virus type 1 (HSV-1) encoding GM-CSF, for the
treatment of advanced melanoma in 2015 [5]. The phase 3
clinical trial which led to the approval of T-VEC demon-
strated a 26.4% objective response rate, and a 10.8%
complete response rate (rising to 17% at the time of the
final analysis [Amgen ODAC presentation May 2015] [6]),
in a 436-patient phase 3 study in patients with both previ-
ously treated and previously untreated Stage IIIb-IVM1c
disease [5].
The therapeutic potential of T-VEC can be further
enhanced by combination with immune checkpoint in-
hibitors. In a small phase 1 trial in patients with melan-
oma, T-VEC in combination with pembrolizumab
resulted in a 62% response rate and 33% complete
response rate [7]. Similarly promising response rates (> 50%)
have also been seen in other small studies with either
ipilimumab or pembrolizumab in combination with other
oncolytic viruses, such as Cavatak (an oncolytic Coxsackie-
virus) or HF10 (another oncolytic HSV-1) [4]. Data have also
been reported from a 200-patient randomized controlled
phase 2 clinical trial with T-VEC combined with ipilimumab
compared to ipilimumab alone, where more than a doubling
of the response rate was seen in the combination arm [8].
While these studies were all in melanoma, it is important to
note that none reported significant additional toxicity
compared to that expected with either agent alone. Based
on the favorable therapeutic window for T-VEC and other
oncolytic viruses, there has been considerable interest in
optimizing the oncolytic immunotherapy strategy and using
such agents as part of a rational combination regimen in
patients with solid cancers.
It is now generally accepted that patients responding
to immunotherapy need to have tumors that are im-
munologically ‘hot’, i.e. have a T cell-inflamed phenotype,
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although the specific mechanisms that regulate T cell re-
cruitment into established tumors are incompletely
understood [9]. Additional factors that favor immune-
mediated rejection include high mutation burden,
presence of pre-existing immune responses to tumor an-
tigens, particularly tumor neoantigens, and expression of
a pro-inflammatory gene signature [10]. While a number
of approaches are in development aimed at correcting
these deficiencies in non-responsive patients, oncolytic
immunotherapies may have particular promise for this
purpose as they kill tumors in a highly inflammatory
context. This effect is highly immunogenic, including
activation of both innate and adaptive immunity, with
the potential to create a vaccine “in situ” within the pa-
tient against their own cancer. The local production of
type 1 interferons induced by oncolytic viruses also
results in increased expression of several immune regu-
latory proteins, including MHC class I and PD-L1 [4].
Thus, oncolytic immunotherapy appears to be particu-
larly well suited for combination strategies with immune
checkpoint blockade. We sought to further optimize the
approach by maximizing (i) the extent of tumor cell
killing, augmenting the release of tumor antigens and
danger-associated molecular pattern (DAMP) factors; (ii)
the immunogenicity of tumor cell death; and (iii) the
resulting systemic anti-tumor immune response. While a
range of viral species were considered for development,
HSV-1 was selected for several reasons. First, HSV-1 is a
very lytic DNA virus; it infects human tumor cells
broadly, and when ICP34.5 is deleted exhibits preferen-
tial replication in neoplastic tissue. Second, HSV-1 kills
mainly by necrosis and activates innate immunity,
including through the cGAS/STING pathway. Third,
HSV-1 has a large capacity for the insertion of
additional, potentially therapeutic, exogenous genes.
Finally, HSV-1 has a proven safety and efficacy profile in
patients with cancer. While intravenous administration
was also considered, an intratumoral approach, i.e. local
administration providing systemic immune-based bene-
fit, was selected based on prior clinical validation and
the considerable, and potentially insurmountable,
biological hurdles to effective intravenous dosing [4, 11].
HSV-1 causes cold sores in humans and is widely preva-
lent in the population, with up to 90% of individuals
testing seropositive by the age of 65 [12]. However,
substantial natural variation might be expected amongst
clinical strains of HSV-1 (i.e. as sampled from individ-
uals suffering from cold sores) with respect to evolved
biological properties such as virulence. This natural
variation might also translate into differences in non-
evolved properties, such as the ability to infect and kill
human tumor cells. Based on the hypothesis that proto-
typical ‘laboratory’ strains of HSV-1, such as Strain 17+,
KOS or Strain F may have become attenuated through
extended serial passage or may otherwise not be optimal
strains for cancer therapy, T-VEC was initially derived
from a clinical strain of HSV-1 after comparing two
clinical isolates to Strain 17+. Both of the clinical strains
were superior for human tumor cell killing compared to
Strain 17+, and the most promising of the two, Strain
JS1, was chosen and engineered into T-VEC [13].
In this report, we describe the generation and
characterization of a new HSV-1-based oncolytic im-
munotherapy platform which utilizes a strain of HSV-1
selected from twenty nine newly isolated clinical strains
on the basis of increased oncolytic activity in vitro. This
was then engineered for tumor selectivity and to express
a potent fusogenic membrane glycoprotein (GALV-GP-
R−) to increase the extent and immunogenicity of tumor
cell death. Various fusogenic proteins including from
measles virus and various retroviruses have previously
been tested in replicative and non-replicative virus-me-
diated gene therapy approaches to the treatment of can-
cer in pre-clinical models [14], including when delivered
by oncolytic versions of HSV [15]. Fusogenic cell death
has also previously been demonstrated to be highly im-
munogenic [14]. Genes encoding GM-CSF, an anti-
CTLA-4 antibody-like molecule and a number of im-
mune co-stimulatory pathway-activating ligands were
then inserted, intending to further enhance the systemic,
immune-mediated, anti-tumor effects achieved.
Methods
Assessment of GALV-GP-R− mediated fusion
The cell lines used for the fusion assays were A549
(ECACC 91072201), HT29 (ECACC 91072201), HT1080
(ECACC 85111505), MDA-MB-231 (ECACC 92020424),
miaPaCa-2 (ECACC 85062806) and SK-mel-28 (ATCC®
HTB-72™). The monolayers were infected using a range
of multiplicity of infection (MOI) from 0.01 to 0.0001.
The infected cell monolayers were observed for GFP
expression at 24 h. and 48 h. post-infection and then
fixed and stained with crystal violet.
Western blots and ELISA
For detection of anti-CTLA-4 expressed from Virus
27, supernatant was used from BHK cells infected at
MOI =1 in serum-free mediuma for 24 h. The proteins
were separated on 10–20% sodium dodecyl polyacryl-
amide gel (Thermo Fisher CAT No: XP10200BOX) and
transferred to polyvinylidene difluoride membrane (Life
Technologies Cat No: LC2005). The membrane was
probed with goat anti-mouse IgG1 heavy chain (alkaline
phosphatase) (Abcam Cat No: ab97237). BCIP®/NBT
Liquid Substrate System (Sigma Aldrich Cat No: B1911)
was used for the detection.
For detection of CD40L, 4-1BBL and OX40L from
Viruses 32, 33 and 35, respectively, BHK cells were
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infected at MOI =1 for 24 h. To confirm expression of
4-1BBL from Virus 33, microplates were coated with the
capture antibody (0.5μg/ml, R&D Systems Cat No:-
AF1246) and incubated overnight at 4 °C. Following
blocking, standards (R&D Systems Cat No 1256-4 L, 40
ng/ml- 0.63 ng/ml) and samples were added and
incubated at 37 °C. The wells were then probed with
anti-mouse 41BBL (Bioxcell Cat No: BE0110) after
which HRP Tagged antibody (Sigma Aldrich Cat No:
A5795) was added and incubated for 1 h. TMB was
added and incubated for 5 mins and sulphuric acid was
added to stop the reaction. The plates were read at 450
nm. ELISA for CD40L (Abcam Cat No: ab119517) and
OX40L (Thermo Fisher Cat No: EMTNFSF4) was
performed using kits as per the manufacturer’s
instructions.
ATP release
Cells were plated at 2 × 105 cells per well in 1 mL, in 12-
well plates, and incubated overnight. Cells were then
infected with Virus 23 or Virus 17 the following day.
Twenty-four and 48 h after treatment, cell supernatants
were collected and centrifuged at 2000 rpm for 4 mins.
Cell-free supernatants were then measured for ATP by
CellTiter-Glo Luminescent Cell Viability Assay (CTG,
Promega, UK). Fifty microliter of CTG was added per
200 uL sample and incubated for 10 min. Luminescence
was measured on a Victor 2 V plate reader (Perkin
Elmer).
High mobility group box 1 protein (HMGB1) release
Cells were plated at 2 × 105 cells per well in 1 mL, in 12-
well plates, and incubated overnight. Cells were infected
with Virus 23 or Virus 17 the following day. Forty-eight
h after treatment, cell supernatants were collected and
centrifuged at 2000 rpm for 4 mins. Cell-free superna-
tants were then measured for HMGB1 by an ELISA
Assay (IBL International GmbH Cat No: ST51011) as
per the manufacturer’s instructions.
Cell surface calreticulin expression
Cells were plated at 2 × 105 cells per well in 1 mL, in 12-
well plates, and incubated overnight. Cells were infected
with Virus 23 or Virus 17 the following day at various
MOI. Forty-eight h after treatment, un-permeabilized
samples were stained with viability dye (Thermo Fisher
Cat No: 65–0865-14), with anti-calreticulin antibody
(Abcam Cat No: ab92516), or isotype control antibody
(Abcam Cat No: ab172730), and flow cytometry was
performed. Surface calreticulin expression was shown as
median fluorescence intensity (MFI). Data was analyzed
using FlowJo software.
In vivo efficacy testing
Bilateral mouse A20 lymphoma tumors were grown in
of Balb/c mice or human A549 or MDA-MB-231 tumors
grown in the right flanks of Balb/c nude mice until aver-
age tumor diameters were > 5 mm. Right flank tumors
were then injected 3 times (every other day) with the
indicated virus and dose in 50 μl or with vehicle (PBS)
and tumor diameters were then followed. For experi-
ments in rats, rat 9 L glioma tumors were grown in the
left and right flanks of Fischer 344 rats until tumors were
0.75-1 cm in diameter and right flank tumors then dosed
5x (approximately every other day) with the indicated
virus at a dose of 5 × 106 pfu in 50 μl or with vehicle and
tumor diameters then followed. For experiments in
combination with anti-murine PD1, clone RMP1–14
(BioXCell) was given by the intraperitoneal route at 10
mg/kg every 3 days for a total of 9 doses.
Vectra staining
Vectra staining was performed on tumors to identify
tumor infiltrating immune cells as previoulsy described
[16]. Bi-flank 4434 murine melanoma tumours grown in
C57BL/6 mice were treated with Virus 16 on days 1, 3
and 5, then collected at day 10 after the first injection,
fixed overnight in 10% neutral buffered formalin and
then transferred to PBS prior to processing and
embedding. Tissue sections were labeled with immuno-
fluorescent stains as follows; CD8 (Cat No: 14–0808-82),
CD4 (Cat No:14–9766-82), and foxp3 (Cat No: 14–
5773-82), all from eBioscience. Images were then quanti-
fied by an automated cell segmentation and phenotyping
algorithm, using inForm analysis software (Perkin
Elmer). Four thousand four hundred thirty-four cells are
a murine melanoma tumor cell line generated in house
at The Institute of Cancer Research, London.
FACS analysis of tumours
C57BL/6 mice were subcutaneously implanted with
4 × 106 4434 murine melanoma cells suspended in 0.1
mL PBS per flank in a bi-flank model. Tumours were
allowed to grow to 6–8 mm and randomized into
study groups. The right flank was injected with 5 × 106
plaque forming units (pfu) of Virus 16 in 50 μl or a mock
group received formulation buffer (vehicle), given on days
1, 3 and 5. Mice were euthanized when a tumour reached
15 mm in any direction. Tumours were harvested and
minced with scissors in digestion mix (0.01% trypsin,
2.5 mg/mL collagenase, 2 mg/mL dispase and 1mg/mL
DNAse in RPMI), and incubated at 37 °C for 30min.
Thereafter, samples were kept on ice. Suspensions were
passed through a 70 μm strainer using a 2.5mL syringe
plunger and washed through with RPMI + 5mM EDTA
until only connective tissue remained. Samples were
centrifuged at 1500 rpm, for 5 mins at 4 °C) and
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transferred into a V-well 96 plate. Samples were stained in
FACS buffer (PSB + 5% FCS) with the following extracellu-
lar antibodies for 30mins, on ice and protected from light;
CD3 (Cat No: 100236), CD4 (Cat No:100406), CD8 (Cat
No: 100732) all from BioLegend, PD-L1 (BD Biociences
Cat No: 558091), and viability dye (Thermo Fisher Cat
No: 65–0865-14). Cells were then washed in FACS buffer
and permeabilized and stained with intracellular antibody
to foxp3 (Thermo Fisher Cat No: 48–5773-80). Samples
were then washed and fixed (1–2% PFA) prior to analysis
of tumour infiltrating lymphocytes by flow cytometry.
Tumours were weighed on collection and counting beads
were added when running the analysis in order to calcu-
late cells per mg of tumour.
Viral replication
Bi-flank 4434 tumours were collected by dissection,
homogenized with 600 μl of serum-free DMEM and cen-
trifuged at 3600 rpm. For 5 mins. Tumor draining lymph
nodes corresponding to the injected and contralateral
tumors and spleens were collected separately.
Supernatants were titred on BHK cells plated at 1 × 104
per well in 96 well plates. Cytopathic effect (CPE) was
scored 48–72 h later and viral titer was determined by
TCID50 assay.
Viral propagation
All viruses used in the study were propagated using a
standard laboratory HSV-1 propagation protocol as de-
scribed previously [17]. In brief, monolayers of vero cells
were infected and virus allowed to seed for 2–3 h after
which the monolayer was washed with growth media
which was replaced and the cells then left in culture
until 100% CPE was observed. Virus was harvested from
the supernatant and a standard HSV-1 plaque assay per-
formed to quantify the virus [18].
Statistical analysis
All statistical analyses were performed using GraphPad
Prism software version 7.0a. Tumor growth curves, flow
cytometric data and immunohistochemistry counts were
compared using an unpaired student’s t test (two-tailed),
one-way ANOVA or two-way ANOVA when multiple
comparisons were performed. P values of less than 0.05
were considered significant. The Figures use the follow-
ing indications of the level of significance: * = p < 0.05,
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
Results
Selection of the virus strain for development
We sought to extend the hypothesis that strains of HSV-
1 with greater oncolytic potential could be derived from
a larger sampling of HSV-1 cold sore isolates. To accom-
plish this, we recruited 126 volunteers who suffered
from herpes cold sores between May 2015 and Aug
2015 and, after obtaining informed consent, collected
viral swab samples from these volunteers during a recur-
rent episode of cold sores. Samples were cultured from
twenty nine volunteers. These were confirmed to be
HSV-1 by anti-HSV-1 antibody staining of infected BHK
cell monolayers and then compared against each other
across a panel of human tumor cell lines representative
of different tumor histologies for their ability to infect
and kill rapidly and at low virus dose. As expected, con-
siderable variation in these abilities was seen, with
roughly one-third of the isolates being relatively poor,
roughly one-third being ‘average’, and nine clearly being
more effective than the rest. These nine isolates were
then compared more thoroughly across the cell line
panel, allowing the generation of a rank order of the top
five isolates. Representative data at only an individual
time point and MOI in each case are shown in
(Additional file 1: Figure S1A). Strain RH018 was chosen
as the strain for further development on the basis that it
scored either first or second most effective at cell killing
on each of the cell lines tested. Compared to a represen-
tative ‘average’ strain from the screen, i.e. a strain from
the middle-third group (isolate RH065), RH018 yielded
approximately a 10-fold increase in cytotoxic potency, as
defined by isotoxic efficacy at a 10-fold lower multipli-
city of infection (Additional file 1: Figure S1B). Isolate
RH018 was sequenced, confirming the presence of the
expected HSV-1 encoded genes, but with a variety of
small changes across the genome as compared to the
originally sequenced prototype HSV-1 genome sequence,
Strain 17+ (Genbank NC_001806.2). No attempt was
made to determine which of the observed changes,
individually or in combination, may be responsible for
the improved (as compared to the ‘average’ clinical strain
of HSV) tumor cell cell killing properties observed.
Based on this screen, the RH018A strain of HSV-1 was,
therefore, selected as a foundation for further development.
Engineering for use as an oncolytic virus
To render strain RH018 non-pathogenic and replication-
selective for tumors, the HSV-1 genes encoding infected
cell protein (ICP) 34.5 and ICP47 were deleted. ICP34.5,
the so-called neurovirulence factor, has functions which
include overcoming host anti-viral (i.e. interferon-medi-
ated) responses which would otherwise block virus repli-
cation in normal tissue, and the expression of which is
essential for pathogenicity [19, 20]. Deletion of ICP34.5
inhibits replication in normal tissue but ICP34.5 is dis-
pensable for replication in tumors [14] by virtue of their
generally having impaired interferon-mediated responses
through various mechanisms [21]. ICP47 is an inhibitor
of antigen presentation in HSV-1 infected cells [22], the
deletion of which also increases the expression of the
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HSV US11 gene by placing the coding sequence for
US11 adjacent to the immediate/early promoter for
ICP47 [13]. US11 has functional redundancy with
ICP34.5 and immediate/early expression of US11
restores to HSV-1 some level of resistance to interferon
[23]. This increases replication in tumors, without redu-
cing the tumor selectivity achieved through the deletion
of ICP34.5 [13]. ICP34.5- and ICP34.5/47-deleted
versions of HSV-1 have been extensively tested in clin-
ical trials [24] and T-VEC (which has both the ICP34.5
and ICP47 deletions) is U.S. FDA approved for the treat-
ment of advanced melanoma. In all cases, these viruses
have been shown to be well tolerated, including through
direct intracerebral injections in patients with glioma
[25]. This proven safety and efficacy profile provided the
basis for using the same disabling approach here. All
viruses were generated by recombination of viral and
plasmid DNA using standard methods, followed by
clone selection based on the presence or absence of GFP
[26]. The genome structures of the viruses constructed
and tested in this paper are shown in (Fig. 1). The details
of the construction of each virus is described in the
Additional file 1.
Augmenting the natural ability of HSV-1 to kill tumor
cells
In order to augment the natural ability of HSV-1 to kill
tumor cells, a codon-optimized version of a potent fuso-
genic membrane glycoprotein (GP) from gibbon ape
leukemia virus (GALV) was additionally encoded in the
virus backbone. Here, the R sequence was deleted (R−),
which provides constitutive fusion properties to the
GALV-GP [14]. The initial viruses constructed to test
this approach expressed either GFP or GFP together
with GALV-GP R− (Virus 10 and Virus 12) (Fig. 1),
which were first tested on a range of tumor cell lines in
vitro. This demonstrated that potent cell-to-cell fusion
was achieved through the expression of GALV-GP-R−,
and that the plaques generated by these viruses were
greatly enlarged, as visualized by expression of GFP
(Fig. 2a). Cell killing potency was also greatly increased,
with substantially greater killing being achieved at
equivalent virus doses through the expression of GALV-
GP-R− across multiple cell lines (Fig. 2b). Next, the
effects of GALV-GP-R− were assessed in human tumor
models in nude mice in which A549 and MDA-MB-231
tumor cells were grown in the flanks of mice and various
doses of the viruses were tested for their ability to treat
these pre-existing tumors. Again, expression of GALV-
GP-R− was seen to significantly enhance anti-tumor
activity (Fig. 2c-d), even when the viruses were used at
low dose levels (data with the viruses used at a 5 × 103
pfu dose level are shown).
As GM-CSF has been included in a number of oncoly-
tic viruses in clinical trials where clinical activity has
been demonstrated, a codon-optimized version of the
gene for mGM-CSF was also encoded in the base plat-
form virus constructed (Virus 16)(Fig. 1) into which fur-
ther genes would then subsequently be inserted. GM-
CSF was driven by a CMV promoter, and as for the
GALV-GP-R− encoding gene also inserted into the
ICP34.5 locus. The function of GM-CSF is to aid in the
maturation and function of dendritic cells (DC) and to
enhance the activity of macrophages, intended to lead to
enhanced anti-tumor immunity [27].
Expression of GALV-GP-R− by the virus further
augmented immunogenic cell death in human and rat
tumor cell lines
To test whether the expression of GALV-GP-R−
increased immunogenic cell death (ICD), A375, A549,
9 L and MDA-MB-231 tumor cell lines were treated
with viruses with and without the insertion of the
gene encoding GALV-GP-R−. After 24 or 48 h., cell
supernatants and/or cell surfaces were assessed for
levels of well characterized markers of ICD (ATP,
HMGB1 and calreticulin) [28]. Infected cells demon-
strated a dose-related increase in ATP from A375,
A549, 9 L and MDA-MB-231 cells (Fig. 3a), and in
HMGB1 from A375, A549, 9 L, and MDA-MB-231
cells (Fig. 3b), and also exhibited an increase in sur-
face staining for calreticulin on A375, A549, 9 L, and
MDA-MB-231 cells (Fig. 3c). All the ICD markers
were substantially increased through the use of the
virus expressing GALV-GP-R− as compared to the
otherwise equivalent virus which did not express
GALV-GP-R−.
Expression of GALV-GP-R− further augments systemic
anti-tumor effects
While the receptor for GALV-GP, PiT1, is expressed
in all mammalian cells [29], the murine version of
PiT1 is incompatible with GALV-GP and no fusion
(or infection with GALV itself ) occurs. Rat PiT1 is,
however, compatible with GALV-GP, and rats were
therefore used to assess the effects of GALV-GP-R−
expression in an immune competent bilateral tumor
model. Rats also allow larger tumors to be studied
than is possible in mice, and murine GM-CSF is also
partially functional in rats [30, 31]. Here, rat 9 L
tumor cells were implanted in both flanks of rats and
then tumors in the right flank were treated with a
virus expressing only mGM-CSF (Virus 19) or ex-
pressing both mGM-CSF and GALV-GP R− (Virus 16)
(Fig. 4). In these experiments, tumor regression was
seen in both injected and uninjected tumors with a
significantly enhanced effect through the expression
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of GALV-GP-R−. While the experiment shown in Fig.
4a was sufficient to demonstrate these enhanced ef-
fects mediated through the expression of GALV-GP-
R−, the study period was relatively short. As a result,
a further experiment was conducted (Fig. 4b) where
animals were treated with vehicle or Virus 16 and
followed to 60 days. This demonstrated that both the
injected and contralateral tumor in seven of ten ani-
mals completely regressed and that treated rats
remained tumor free until the termination of the
experiment.
Treatment with virus 16 increases CD8+ T cell infiltration
and PD-L1 expression levels in tumors
To confirm the hypothesis that local treatment with
Virus 16 increases levels of infiltrating CD8+ T cells,
bilateral 4434 tumors were established in the flanks
of immune competent C57BL/6 J mice and treated as
described in Methods with Virus 16 injected into the
right flank tumor. Injected and un-injected tumors
were harvested at 10 days following injection and
assessed for the presence of CD8+ T cells, CD4+ T
cells and CD4 + FoxP3+ regulatory T cells (Tregs) by
Fig. 1 Schematic representation of the viruses constructed in this study. The genome structures of the viruses constructed and tested. The
construction of each virus is described in detail in the Additional file 1
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immunohistochemical (IHC) assessment using the
Vectra platform as previously described [16] (Fig. 5a).
While there was only a limited effect on the level of
CD4+ T cells and no obvious effects on Tregs, there
was a significant increase in CD8+ T cells in both
injected and contralateral uninjected tumours in
virus-treated animals, but not in vehicle-treated con-
trols (Fig. 5a). PD-L1 levels could not be assessed by
IHC due to the inability to identify a suitable anti-
mouse PD-L1 antibody for use in IHC. However, flow
cytometry analysis demonstrated a significant increase





Fig. 2 The effects of GALV-GP-R− expression on human tumor cell lines in vitro and human tumor xenograft models in vivo. a Images of cell
lines infected with Virus 12 (expresses GFP) top panel and (a) Images of cell lines infected with Virus 10 (expresses GFP and GALV-GP-R−). b
Images representing the cell killing effects of Virus 12 and (b) Virus 10 in a panel of tumor cells. c Individual tumor growth curves from mice
treated with either vehicle, Virus 19 (expresses mGM-CSF) or Virus 16 (expresses mGM-CSF and GALV-GP-R−) in the A549 lung cancer model and
(d) in the MDA-MB-231 breast cancer model. The dose level of virus was in each case 5 × 103 pfu in 50 μl given 3x every other day. Statistical
differences between groups were measured by one-way ANOVA at day 41 for the A549 model and at day 38 for the MDA-MB-231 model. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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C
Fig. 3 Markers of immunogenic cell death in cells treated with either Virus 23 (expresses hGM-CSF) or Virus 17 (expresses hGM-CSF and + GALV-
GP R-) in vitro. a Levels of ATP release measured by luminescence in a panel of cell lines treated at the indicated MOI at 24 h post infection and
(a) at 48 h post infection observed in cell-free supernatants treated with Virus 23 (indicated by the clear bars) and Virus 17 (indicated by the solid
bars). b ELISA measuring HMGB1 (pg/ml) levels in cell-free supernatants from cells treated for 48 h with MOI 0.0001–1. c Histogram showing the
expression levels of surface calreticulin (CRT) in cells treated at indicated MOI 0.01 for 48 h. Data show un-permeabilized, viable cells stained with
CRT and measured by FACS. Statistical differences between groups were determined by using two-way ANOVA, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001
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predominantly in injected tumors in virus-treated ani-
mals but not in vehicle-treated controls (Fig. 5b).
FACS analysis also demonstrated that the relative
frequency of CD8+ T cells were significantly increased
in the injected (ipsilateral) and un-injected (contralat-
eral) tumors at day 10 (Fig. 5c). A significant increase
A
B
Fig. 4 Effects of GALV-GP-R− expression in an immune competent tumor model. a Tumor growth curves of rat 9 L tumors treated with either
vehicle (PBS), Virus 19 (expresses mGM-CSF) or Virus 16 (expresses mGM-CSF and GALV-GP R−). Virus or vehicle were injected into the right tumor
only. b A repeat of the experiment in (A), treating with either vehicle or Virus 16 but with longer follow up until day 60. 5 × 106 pfu of virus in
50 μl was given 5x every other day in each case. Statistical differences between groups were measured by one-way ANOVA at day 31 for a and at
day 35 for b. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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in CD8+ T cells was also observed in the draining
lymph nodes from injected tumors in treated mice at
day 16 as compared to vehicle-treated control animals
(Fig. 5d).
Virus 16 productively replicates in injected tumors
To confirm that Virus 16 replicated in injected tumors,
a time course experiment was conducted where mouse





Fig. 5 Tumors from Virus 16 treated animals demonstrate increased levels of CD8+ T cells and PD-L1. a Immunohistochemistry staining for CD8
(red), CD4 (green) and foxp3 (pink) of injected and un-injected 4434 tumors from mice either treated with mock or with Virus 16 (expresses
mGM-CSF and GALV-GP R−) 10 days after treatment. b Relative frequency of PD-L1+ cells in mice bearing 4434 bi-flank tumours treated in the
right flank with Virus 16 or vehicle on days 1, 3 and 5 and collected on days 3, 7, 10 and 16 after the first day of treatment. c The relative
frequency of tumor infiltrating CD8+ cells, gated from the viable cell population, from tumours collected on days 3, 7, 10 and 16. d The relative
frequency of CD8+ cells from lymph nodes at days 3, 7, 10 and 16. Statistical differences between groups were determined by using two-way
ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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previously described. Virus 16 was injected into the right
tumor and then left and right tumors harvested at 3, 7
and 10 days and the levels of live virus present per
tumor determined by titration on BHK cells. This dem-
onstrated that virus was detected at levels at least equal
to the input level of virus until Day 7 in injected tumors
and at lower levels in draining lymph nodes, but no virus
was detected at any time in uninjected tumors (Add-
itional file 1: Figure S2). This further confirmed that the
virus remains localized to sites of injection and anenestic
effects are due to immune-mediated systemic effects,
and not due to the trafficking of virus from injected to
uninjected contralateral tumors.
Confirmation of synergy with immune checkpoint
blockade
Based on prior evidence of clinical synergy between
oncolytic therapy and immune checkpoint blockade
[7, 8] and on the increased expression of PD-L1 in-
duced by Virus 16, we sought to evaluate the effects
of the combination of Virus 16 and PD-1 blockade in
vivo. For this experiment the bilateral murine A20
lymphoma tumor model was used as these cells are
susceptible to HSV-1, immune competent mice can
be used, and anti-murine PD-1 antibodies are avail-
able to test the combination, although no GALV-GP
R− mediated effects will be seen. While anti-PD-1
treatment alone demonstrated minimal if any activity
in this relatively anti-PD1 resistant model (Fig. 6a),
enhanced anti-tumor effects were seen in both
injected and uninjected tumors with Virus 16 in com-
bination with anti-PD1 antibody therapy as compared
to either therapy alone (Fig. 6b-d). These effects were
most evident at low virus dose where the virus alone
is least effective, and also particularly evident in unin-
jected tumors where the combination led to a signifi-
cant enhancement of the anti-tumor effect (Fig. 6d).
Figure 6b-d shows data using three dose levels of
Virus 16 alone and in combination with murine anti-
PD1, with in each case increased activity of the com-
bination as compared to single agent treatment.
Systemic effects can be further augmented through
arming with anti-CTLA-4 or immune co-stimulatory
pathway-activating ligands
Virus 16, which expresses mGM-CSF and GALV-GP-R−,
was then further developed to take advantage of the
capacity of HSV-1 to encode other proteins intended to
further augment the anti-tumor immune response. Thus,
with these considerations in mind, to test these concepts
Virus 16 was further engineered to express either an
anti-mouse CTLA-4 antibody-like molecule or mouse
CD40L, mouse OX40L or mouse 4-1BBL (Fig. 1).
Following confirmation of expression by western blot
analysis for anti-mouse CTLA-4 (Fig. 7a) and by ELISA
for mCD40L, m4-1BBL and mOX40L (data not shown),
these viruses were tested in the mouse bilateral A20
model, using a low virus dose (5 × 104 pfu) which at that
dose does not mediate a substantial anenestic effect in
non-injected tumors for Virus 16. This demonstrated
that virus-mediated delivery of each of these proteins
was effective at increasing the antitumor effect, not only
in injected tumors but more markedly in un-injected tu-
mors (Fig. 7b). A further experiment where 15 mice pre-
viously cured of bilateral tumors were challenged with
new tumor cells on the contralateral flank on day 108
demonstrated that these anti-tumor effects in combin-
ation with anti-PD1 are highly durable (Additional file 1:
Figure S3A) and that due to the demonstrated protection
of fourteen of the fifteen mice from re-challenge that ef-
fective memory immune responses had been induced.
Anti-PD1 alone in this experiment had no significant anti-
tumor effect (Additional file 1: Figure S3B).
Discussion
In this study, we reported the development of a new
oncolytic immunotherapy platform based on HSV-1
starting with a new clinical strain of HSV-1 isolated
from an individual with herpes cold sores. This strain,
RH018A was found to have broad lytic activity across
a range of tumor cell lines in vitro. The new virus
strain was developed for oncolytic use by deletion of
the ICP34.5 and ICP47 encoding genes and insertion
of a gene encoding the fusogenic protein GALV-GP-
R−. HSV-1 is a naturally highly lytic virus which kills
infected cells rapidly, and at low dose. Release of
tumor antigens through this process would be ex-
pected to be highly immunogenic, but, even so, im-
provements to these properties would be beneficial. A
number of fusogenic proteins, including from measles
virus and a number of retroviruses have previously
been tested in various gene therapy and oncolytic ap-
proaches to treating cancer, including when expressed
from oncolytic HSV-1 [14]. However, while in all
cases a high degree of anti-tumor efficacy was seen in
pre-clinical models, with GALV-GP-R− showing par-
ticular promise, no fusogenic approach to cancer
therapy (oncolytic or otherwise) has previously pro-
gressed to clinical trials. GALV-GP-R− kills cells by
cell-to-cell membrane fusion (syncytium formation)
following binding to the constitutively expressed PiT1
receptor for GALV [29]. This mechanism provides a
large bystander effect around each infected cell, in-
creasing the area of killing achieved. It has also been
demonstrated that GALV-GP-R−-mediated cell death
is highly immunogenic [14]. For these reasons, i.e. the
potential to increase both the extent of tumor killing
achieved and the immunogenicity of cell death,
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GALV-GP-R− was included in the viruses developed
here. GM-CSF was also included in the base platform
virus from this program (Virus 16) since a number of
oncolytic viruses in clinical trials have also encoded
GM-CSF and clinical activity has been demonstrated,
including talimogene laherparepvec which is U.S. FDA
approved for the treatment of advanced melanoma
[5], CG0070, an oncolytic adenovirus [32], and JX-594
(Pexavec; an oncolytic vaccinia virus [33].
GALV-GP-R− expression was demonstrated to increase
ICD in vitro as demonstrated by increased exposure of
ecto-calreticulin and release of intracellular ATP and
HMGB1. We also observed an increase in both local (i.e.
injected or enestic) and systemic (i.e. uninjected or ane-
nestic) [34] anti-tumor effects in unilateral mouse xeno-
graft and/or bilateral tumors in immune competent rats.
Increased CD8+ T cells and PDL1 expression levels in
tumors were also observed. Consistent with the in-
creased expression of PD-L1, we also found further
improvement in therapeutic responses in combination
with PD1 blockade in immune competent mice bearing
established A20 tumors. In order to test the impact of
GALV-GP-R− in an immune competent host, we utilized
the rat 9 L glioma model since rats, unlike mice, express
A B
C D
Fig. 6 Effects of combination treatment with Virus 16 and anti-PD1. a-d Individual tumor growth curves of injected (right) and contralateral/un-
injected (left) tumors from BALB/C mice bearing A20 lymphoma tumors treated with either (a) vehicle or anti-PD1, b Virus 16 (5 × 106 pfu/dose
3x), or Virus 16 (5 × 106 pfu/dose 3x) and anti-PD1, c Virus 16 (5 × 105 pfu/dose 3x) or Virus 16 (5 × 105 pfu/dose 3x) and anti-PD1 and (d) Virus 16
(5 × 104 pfu/dose 3x) or Virus 16 (5 × 104 pfu/dose 3x) and anti-PD1. Statistical differences between groups were measured by one-way ANOVA
with multiple comparisions at day 28. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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a version of the PiT1 receptor which is compatible with
GALV-GP-R−. In this model, Virus 16 also demonstrated
significant tumor regression in both injected and unin-
jected tumors, which is particularly notable since the
tumors in this model are substantially larger than is
possible in mice. Collectively, these data support the
clinical development of the human version of Virus
16, i.e. expressing human rather than mouse GM-CSF
(Virus 17; RP1), which has entered clinical trials in a
number of solid tumor types in combination with
anti-PD1 therapy [35].
This prototype and initial clinical development candi-
date virus was then used as the basis from which to
express further therapeutic genes aimed at amplifying
the immune effects achieved. Here, the intention was to
focus on the delivery of genes encoding proteins which
exert their action at the site and time of immune
response initiation (i.e. in injected tumors and draining
lymph nodes), rather than through expression of pro-
teins which would be required systemically to have
their maximum effect. An example of the former in-
cludes CTLA-4 blockade, as CTLA-4 inhibits the
induction of immune responses by competing with
CD28 for binding to B7 on antigen presenting cells,
making local intratumoral delivery an attractive
option. An example of the latter would include anti-
PD1 or -PD-L1 antibodies, since the PD1/L1 interaction
inhibits the effector immune response systemically at
the T cell/tumor interface, rendering local, virus-
driven expression less appealing. Immune co-stimula-
tory pathway-activating proteins are also inviting can-
didates for intratumoral delivery, since they are
expected to act at the site of immune response initiation
to stimulate T cells. In addition, for these potentially toxic
molecules, intratumoral delivery would restrict expression
to the tumour compartment and might be expected to re-
duce the side effects that have occurred with systemic ag-
onistic antibody-based approaches.
Initial viruses expressed an anti-CTLA-4 antibody-like
molecule or immune co-stimulatory pathway-activating
A
B
Fig. 7 Expression of anti-CTLA-4 or immune co-stimulatory pathway activating ligands further increases the efficacy of Virus 16 in vivo. a Western
blot showing the expression of of anti-mouse CTLA-4 as detected in cell lysates from cells infected with Virus 27. b Individual tumor growth
curves of injected and contralateral tumors from BALB/C mice bearing A20 lymphoma tumors treated with either vehicle, Virus 16 (expresses GM-
CSF and GALV-GP R-), Virus 27 (additionally expresses anti-mCTLA-4, Virus 32 (additionally expresses mCD40L), Virus 33 (additionally expresses m4-
1BBL) or Virus 35 (additionaly expresses mOX40L). The dose level of virus was in each case 5 × 104 pfu in 50 μl given 3x every other day. Statistical
differences between groups were measured by one-way ANOVA at Day 40. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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ligands (CD40L, 4-1BBL or OX40L). In each case, local
delivery was demonstrated to increase the anenestic
effect, validating the approach and providing further
candidate viruses for clinical development. Overall, it is
intended that the modular system developed will be used
to express additional candidate therapeutic genes indi-
vidually and in combination as promising candidate target
pathways continue to be identified as the immune-oncol-
ogy field matures.
Conclusion
We report the development of a new oncolytic immuno-
therapy platform based on HSV-1 from the starting
point a new clinical strain of HSV-1 isolated from an in-
dividual with herpes cold sores. This strain, RH018A,
was further developed for oncolytic use by deletion of
the ICP34.5 and ICP47 encoding genes and insertion of
a gene encoding the fusogenic protein GALV-GP-R−.
This led to an increase in the direct oncolytic effect and
in immunogenic cell death in vitro. Treatment of xeno-
graft models demonstrated that GALV-GP R− enhanced
direct tumor killing in-vivo and treatment of a syngeneic
tumor model demonstrated enhanced anenestic re-
sponses. As expected, treatment effects were further im-
proved in combination with PD1 blockade. This
platform virus, which also expressed GM-CSF, was then
used to express further therapeutic genes aimed at amp-
lifying the immune effects achieved, an anti-CTLA-4
antibody-like molecule, or immune co-stimulatory path-
way-activating ligands (CD40L, 4-1BBL or OX40L). In
each case, local delivery was demonstrated to increase
the anenestic effect, validating the approach and provid-
ing further candidate viruses for clinical development.
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